author-photo

Peter Schmid

Queen Mary University of London
CERN
Imperial College London

595

Papers

17548

Citations

Citation Trend

Filter By

Papers (595) Sort By

Journal Conference Others

Experimental Attenuation of a Trailing Vortex Inspired by Stability Analysis

2022
Show All
- Source
- Cite
- Save
Citations (0)
Lagrangian Strain- and Rotation-Rate Tensor Evaluation Based on Multi-pulse Particle Tracking Velocimetry (MPTV) and Radial Basis Functions(RBFs)

2021
Show All
- Source
- Cite
- Save
Citations (0)
Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (8)
Abstract PS5-12: Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC)

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
A Systematic Review and Meta-analysis on the Effect of Neoadjuvant Chemotherapy on Complications Following Immediate Breast Reconstruction

2021 The Breast
Show All
- Source
- Cite
- Save
Citations (3)
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract PD14-06: Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER+ primary breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)